Skip to main content

Table 1 Patients characteristics by cardiovascular diseases at baseline (before and after propensity score 1:1 matching)

From: Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study

  Before Matching After Matching
Variables Mean (S.D.) P-value Mean (S.D.) P-value
  With CVD (N = 406) Without CVD (N = 1536)   With CVD (N = 394) Without CVD (N = 394)  
SU added at index 80.8% 73.6% 0.003 - - -
Glitazones added at index 19.2% 26.4%   - - -
Demographics       
Age (years) 64.3 (9.2) 59.5 (10.5) < 0.0001 64.0 (9.0) 63.9 (10.1) 0.96
Male 65.5% 51.3% < 0.0001 65.0% 70.3% 0.11
Caucasian 98.0% 96.7% 0.17 98.0% 98.4% 0.68
Duration of diabetes (years) 6.1 (5.2) 5.6 (4.8) 0.09 6.0 (5.0) 6.1 (5.0) 0.99
Never used alcohol 27.6% 30.4% 0.29 27.9% 26.1% 0.57
Physical Activity       
   No regular activity 39.1% 34.6% 0.11 37.6% 39.5% 0.58
   < 3 times/week 39.1% 39.7% 0.83 41.0% 36.5% 0.12
   ≥ 3 times/week 21.9% 25.7% 0.12 21.4% 24.0% 0.34
Country       
   Spain 15.8% 28.1% < 0.0001 16.2% 15.0% 0.62
   France 6.9% 8.1% 0.43 7.1% 6.9% 0.89
   UK 26.6% 16.9% < 0.0001 26.7% 26.4% 0.94
   Norway 3.0% 3.4% 0.67 3.1% 4.8% 0.20
   Finland 7.4% 10.7% 0.049 7.6% 10.2% 0.21
   Germany 17.7% 21.4% 0.10 18.3% 19.8% 0.59
   Poland 22.7% 11.5% < 0.0001 21.1% 17.0% 0.15
Baseline Clinical Information       
HbA1c (%) 8.1 (1.3) 8.0 (1.4) 0.69 8.06 (1.26) 8.05 (1.39) 0.96
With HbA1c < 6.5% 5.2% 8.3% 0.037 5.1% 7.6% 0.14
Body mass index (kg/m2) 31.7 (8.2) 31.9 (6.2) 0.60 31.7 (6.6) 31.7 (6.7) 0.94
Physician specialty       
   Endocrinologists/Diabetologists 40.6% 40.6% 0.99 40.6% 41.1% 0.89
   General practitioners/Internists 59.4% 59.4%   59.4% 58.9%  
Duration of metformin use (years) 3.0 (2.9) 2.8 (2.5) 0.15 2.9 (2.7) 2.8 (2.5) 0.60
  1. Note: CVD: cardiovascular diseases; S.D.: standard deviation.